# Nectin-4

Source: https://onco.cc/targets/nectin4/  
OnCo record `nectin4` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nectin-4 is an adhesion protein plentiful on bladder cancer cells, used as the docking site for the ADC enfortumab vedotin.

## Summary

Nectin-4 is expressed at high levels in urothelial carcinoma and also in breast, lung, and pancreatic cancers. Enfortumab vedotin plus pembrolizumab is first-line standard in advanced urothelial cancer (EV-302). Next-generation Nectin-4 ADCs with topoisomerase-I payloads (MK-3120) and Nectin-4×TROP2 bispecific ADCs (AK146D1, AVZO-103) are in development.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: adc-target
- Symbol: NECTIN4
- Class: surface-antigen
- Biology: Nectin-4 is a cell adhesion molecule and also a receptor for measles virus. Skin expression explains the rash seen with enfortumab.
- Where found: Urothelial carcinoma (>80%); TNBC; NSCLC; Pancreatic

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Nectin-4
- Wikipedia: https://en.wikipedia.org/wiki/Nectin-4

## Connected records

- biomarkers: [Nectin-4 expression](https://onco.cc/biomarkers/nectin-4-expression/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Urethral cancer](https://onco.cc/cancers/urethral/), [Urothelial carcinoma of the urethra](https://onco.cc/cancers/urethral-urothelial-carcinoma/)
- drugs: [AK146D1](https://onco.cc/drugs/ak146d1/), [CRB-701](https://onco.cc/drugs/crb-701/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Zelenectide pevedotin](https://onco.cc/drugs/zelenectide-pevedotin/)
- companies: [Aktis Oncology](https://onco.cc/companies/aktis-oncology/), [Avenzo Therapeutics](https://onco.cc/companies/avenzo/), [Emergence Therapeutics](https://onco.cc/companies/emergence-therapeutics/), [Marengo Therapeutics](https://onco.cc/companies/marengo-therapeutics/)
- trials: [Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07299747/), [EV-302 / KEYNOTE-A39](https://onco.cc/trials/ev-302/), [EV-303 / KEYNOTE-905](https://onco.cc/trials/ev-303/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/), [Peptide-drug & small-molecule-drug conjugates](https://onco.cc/technologies/peptide-drug-conjugate/)
- people: [Jonathan E. Rosenberg](https://onco.cc/people/jonathan-rosenberg/), [Thomas Powles](https://onco.cc/people/thomas-powles/)
- key papers: [EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer](https://onco.cc/key-papers/paper-ev-302-nejm-2024/)
- terms: [Overexpression](https://onco.cc/terms/overexpression/)
- pathways: [Mitosis & the spindle assembly checkpoint](https://onco.cc/pathways/mitotic-spindle-checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/nectin4.json